DGAP-News: Novavax to Present at the 13th Annual Needham Healthcare Conference

| Source: EQS Group AG
DGAP-News: Novavax, Inc. /
Novavax to Present at the 13th Annual Needham Healthcare Conference

02.04.2014 / 22:10


GAITHERSBURG, Md., 2014-04-02 22:10 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today
that Stanley C. Erck, President and Chief Executive Officer, will present at
the 13th Annual Needham Healthcare Conference on April 9, 2014 at 12:10 pm ET
in New York City at the Westin Grand Central Hotel. 

A live webcast link for the presentation will be available via the company
website at www.novavax.com under Investor Info/Events. 

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent diseases.
Novavax is involved in several international partnerships, including
collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea
and PATH, and recently acquired Isconova AB, a leading vaccine adjuvant company
located in Sweden. Together, Novavax' network supports its global
commercialization strategy to create real and lasting change in the
biopharmaceutical and vaccinology fields. Additional information about Novavax
is available on the company's website, novavax.com. 

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development
of its vaccine and adjuvant products are forward-looking statements. Novavax
cautions that these forward looking statements are subject to numerous risks
and uncertainties, which could cause actual results to differ materially from
those expressed or implied by such statements. These risks and uncertainties
include those identified under the heading 'Risk Factors' in the Novavax Annual
Report on Form 10-K for the year ended December 31, 2013, filed with the
Securities and Exchange Commission (SEC). Investors are cautioned not to place
considerable reliance on the forward-looking statements contained in this press
release. You are encouraged to read company filings with the SEC, available at
sec.gov, for a discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of the date of
this document, and the company undertakes no obligation to update or revise any
of the statements. The company's business is subject to substantial risks and
uncertainties, including those referenced above. Investors, potential
investors, and others should give careful consideration to these risks and

         Barclay A. Phillips
         SVP, Chief Financial Officer and Treasurer
         Novavax, Inc.
News Source: NASDAQ OMX

End of Corporate News


02.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language:    English        
Company:     Novavax, Inc.  
             United States  
ISIN:        US6700021040   
End of News    DGAP News-Service  
261309 02.04.2014